On Monday, the S&P/ASX 200 Index (ASX: XJO) started the week with the smallest of declines. The benchmark index edged a fraction lower to 8,729.4 points.
Will the market be able to bounce back from this on Tuesday? Here are five things to watch:
Image source: Getty Images
ASX 200 to fall
The Australian share market looks set to fall on Tuesday despite a positive night on Wall Street. According to the latest SPI futures, the ASX 200 is expected to open the day 31 points or 0.35% lower. In the United States, the Dow Jones rose 0.1%, but the S&P 500 climbed 0.25%, and the Nasdaq pushed 0.4% higher.
Oil prices jump
ASX 200 energy shares including Beach Energy Ltd (ASX: BPT) and Santos Ltd (ASX: STO) could have a strong session after oil prices jumped overnight. According to Bloomberg, the WTI crude oil price is up 5.75% to US$92.42 a barrel and the Brent crude oil price is up 4.6% to US$95.29 a barrel. This follows reports that Iran has ended peace talks and vowed to block the Strait of Hormuz.
BHP and Rio Tinto on watch
BHP Group Ltd (ASX: BHP) and Rio Tinto Ltd (ASX: RIO) shares will be on watch on Tuesday after a strong night of trade for their NYSE-listed shares. Both mining giants rose over 2% and ended the session within touching distance of new record highs. This appears to have been driven by another solid rise from copper prices overnight.
Gold price tumbles
ASX 200 gold shares such as Newmont Corporation (ASX: NEM) and Northern Star Resources Ltd (ASX: NST) could have a poor session after the gold price tumbled overnight. According to CNBC, the gold futures price is down 1.7% to US$4,513.9 an ounce. Traders were selling gold after US-Iran peace talks abruptly ended and sent oil prices hurtling higher, sparking inflation and rate hike fears.
Buy Artrya shares
Artrya (ASX: AYA) shares could offer strong returns according to analysts at Bell Potter. This morning, the broker has retained its buy rating and $6.10 price target on the healthcare AI stock. This implies potential upside of almost 30% for investors over the next 12 months. It said: "The recognition of CCTA image analysis by CMS and Physicians to efficiently and effectively detect and diagnose CAD is a huge growth driver for image analysis providers. CCTA utilisation is surging and this provides a strong foundation for AYA's superior product features to capture material market share over our forecast horizon."
